Dutrebis

lamivudine; raltegravir potassium · Merck Sharp & Dohme Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dutrebis, covering 2017-04-27 to 2017-04-27. Get the full timeline:

Most recent: EMA Withdrawn: Dutrebis (lamivudine;raltegravir potassium) — Merck Sharp Dohme Limited